HUTCHMED (NASDAQ:HCM) Shares Down 5.7% - Here's Why

Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) traded down 5.7% during mid-day trading on Friday . The company traded as low as $15.02 and last traded at $14.85. 8,068 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 96,397 shares. The stock had previously closed at $15.74.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Friday, March 21st.

HUTCHMED Stock Down 1.7 %

The company has a fifty day moving average price of $14.96 and a two-hundred day moving average price of $15.72. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.

Hedge Funds Weigh In On HUTCHMED

Institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio grew its holdings in shares of HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after buying an additional 899 shares during the last quarter. Summit Trail Advisors LLC increased its stake in HUTCHMED by 7.7% in the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after buying an additional 1,004 shares during the period. Crossmark Global Holdings Inc. raised its position in HUTCHMED by 10.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock worth $268,000 after buying an additional 1,799 shares during the last quarter. Barclays PLC lifted its stake in shares of HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after acquiring an additional 2,255 shares during the period. Finally, Blue Trust Inc. raised its holdings in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after purchasing an additional 3,532 shares in the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.